MIM
PEAR

MetLife Investment Management’s Pear Therapeutics, Inc. Class A Common Stock PEAR Stock Holding History

MetLife Investment Management’s Portfolio PEAR Stock Details PEAR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-41,941
Closed -$49.5K – 2835
2022
Q4 		$49.5K Buy
+41,941
New +$88.2K ﹤0.01% 2762

Other funds holding PEAR

Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
AV
Arboretum Ventures Ann Arbor, Michigan $1.72M AUM 82.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TAA
TB Alternative Assets Grand Cayman, Cayman Islands $623M AUM 154.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

MetLife Investment Management's PEAR Position: Q1 2023 in Review

MetLife Investment Management sold out of Pear Therapeutics, Inc. Class A Common Stock (PEAR) in Q1 2023, closing a stake of 41,941 shares — an estimated $49.5K sold.

MetLife Investment Management first reported a position in PEAR in Q4 2022 and held it in 1 quarter. The position peaked at $49.5K in Q4 2022. 53 funds tracked by Wall St. Rank hold PEAR as of Q1 2023.

  • MetLife Investment Management reported no remaining Pear Therapeutics, Inc. Class A Common Stock position as of Q1 2023 after selling out during the quarter.
  • MetLife Investment Management sold 41,941 Pear Therapeutics, Inc. Class A Common Stock shares in Q1 2023, an estimated $49.5K.
  • MetLife Investment Management first reported a position in Pear Therapeutics, Inc. Class A Common Stock in Q4 2022 and held it in 1 quarter.
  • MetLife Investment Management's Pear Therapeutics, Inc. Class A Common Stock position peaked at $49.5K in Q4 2022.
  • 53 funds tracked by Wall St. Rank held Pear Therapeutics, Inc. Class A Common Stock as of Q1 2023.

Based on MetLife Investment Management's 13F filing for Q1 2023, filed 15 May 2023.